Endocrine system is made of endocrine glands and hormones that secrete hormones directly into the blood stream that are crucial for regulation of several body mechanisms such as growth, development and homeostasis. The endocrine glands such as pituitary, pineal, thyroid and secretory organs such as pancreas, hypothalamus release hormones directly into the blood stream. Tests are performed to monitor levels of endocrine hormones (such as Follicle stimulating hormone (FSH), Luteinizing Hormone (LH), estradiol, insulin and others) from biological samples. These tests aid in detection of deviation in the hormone production i.e. they help detect either hypersecretion (excess secretion) or hyposecretion (less secretion) that results in certain endocrine disorders such as infertility, menopause, thyroid dysfunction and others. Responses to stress, injury, absorption of nutrients maintenance of water and electrolyte balance and energy metabolism constitutes major areas of control and integration offered by the endocrine system.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/901
The global endocrine testing market is categorized in three major segments; by tests, by diagnostic technology and by end users. The test segment is further categorized into 11 major hormone tests that include estradiol (E2), Follicle Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), Luteinizing hormone (LH), Dehydroepiandrosterone sulfate (DHEAS), progesterone, testosterone, Thyroid Stimulating Hormone (TSH), prolactin, cortisol and insulin tests. The thyroid stimulating hormone (TSH) dominated the global endocrine testing market and would continue to dominate the market during the forecast period growing at a CAGR of 7.5%. This is attributed to high prevalence of thyroid disorders among geriatric population and also is more common in females than males with a female to male ratio of 10:1. However, insulin testing market is anticipated to be the fastest growing segment during the forecast period from 2015 to 2023, where the major reason being constant rise in diabetic and obese population across the globe.
The use of technological platforms for the analysis of several endocrine hormones is essential to ensure precise and accurate test results. The diagnostic technology segment of the endocrine testing market constitutes the analysis of five major technologies: tandem mass spectrometry, monoclonal and polyclonal antibody technologies, immunoassays, sensor, and clinical chemistry technology. The others segment includes liquid chromatography-tandem mass spectro metry (LC-MS/MS). Immunoassay segment held the largest share of diagnostic technology segment growing at a CAGR of 9.1%. Tandem mass spectrometry segment is estimated to be the fastest growing diagnostic technology segment during the forecast period. Major factors driving the growth of several diagnostic technologies include increased laboratory automation and introduction of innovative technologies for analysis. Several end users represent hospitals, commercial laboratories, ambulatory care centers, home based tests and physician offices that facilitate endocrine testing. The commercial laboratories segment held the largest market share in 2014, expanding at a CAGR of 9.3% from 2015 to 2023. While Home-based tests is expected to witness highest growth rate during the forecast period of 2015 to 2023. Increasing preference of the customers towards instant test results followed by low cost supports the growth and adoption of home based test kits over the other end users (hospitals, laboratories).
Inquiry on this report @ http://www.mrrse.com/enquiry/901
Geographically, North America dominated the endocrine testing market in 2014 with a share of 40.6% due to factors such as timely technological upgrade and increased health care awareness among patients. Additionally, increasing incidence of diabetes and obesity and constant rise in the geriatric population creates a need and demand for effective endocrine testing products and technology and thus felicitate the market growth. Asia Pacific is projected to be the most lucrative market for endocrine testing and is expected to expand at the highest growth rate of 10.3% from 2015 to 2023. Factors propelling the growth of the endocrine testing market in Asia Pacific is increased investments by several health care manufacturers in these emerging markets (Japan, China, India, Australia, and others), and higher disposable income,. Moreover, growing medical tourism for in vitro fertility treatments at low cost in developing regions such as Asia compared to developed regions is likely to boost the growth of the endocrine testing market in the region.
Read Complete Report with TOC @ http://www.mrrse.com/endocrine-testing-market
The global endocrine testing market is highly oligopolistic in nature with top five players account for around 90% of the total market. F-Hoffman La Roche Ltd. dominated the endocrine testing market in 2014 with a market share of 23.1%. Major factors attributed to its dominance are broad product portfolio and high market penetration. Abbott Laboratories secured the second market position with a share of 19.3% in 2014 offering a wide array of technological platforms. DiaSorin was followed by Agilent Technologies and Siemens Healthcare holding 16.8%, 15.4% and 13.8% shares, respectively, owing to the presence of a wide range of endocrine testing products and technologies. Other players such as Thermo Fisher Scientific, AB SCIEX LLC, Bio Rad Laboratories, Lab Corporation, bioMerieux, Sysmex Corporation, Ortho-clinical Diagnostics, Quest Diagnostics and Biomedical Diagnostics contributed 11.6% of the total market revenue in the year 2014.
90 State Street,
Albany NY – 12207